In previous studies, we showed that inhibition of oncogene drivers such as EGFR in NSCLC and BCR-ABL in CML caused a downregulation of glycolysis and an upregulation of OXPHOS [22, 23]. This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.